APA (7th ed.) Citation

Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., . . . Bookman, M. A. (2020). A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of clinical oncology, 38(15_suppl), 6003. https://doi.org/10.1200/JCO.2020.38.15_suppl.6003

Chicago Style (17th ed.) Citation

Liu, Joyce F., et al. "A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Recurrent Platinum-sensitive Ovarian Cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): 6003. https://doi.org/10.1200/JCO.2020.38.15_suppl.6003.

MLA (9th ed.) Citation

Liu, Joyce F., et al. "A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Recurrent Platinum-sensitive Ovarian Cancer." Journal of Clinical Oncology, vol. 38, no. 15_suppl, 2020, p. 6003, https://doi.org/10.1200/JCO.2020.38.15_suppl.6003.